Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Urological recommendations from the National Institute for Health and Care Excellence (NICE) Guideline, June 2015: Suspected cancer: recognition and referral.

Jefferies ER, Brewster SF; BAUS Section on Oncology.

BJU Int. 2016 Jun;117(6):857-60. doi: 10.1111/bju.13355. Epub 2015 Nov 14. No abstract available.

PMID:
26473591
2.

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial.

Wade J, Holding PN, Bonnington S, Rooshenas L, Lane JA, Salter CE, Tilling K, Speakman MJ, Brewster SF, Evans S, Neal DE, Hamdy FC, Donovan JL; ProtecT Study Group.

BMJ Open. 2015 Sep 18;5(9):e008953. doi: 10.1136/bmjopen-2015-008953.

3.

Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.

Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch Garcia S, Giles GG, Southey MC, Fitzgerald L, Gronberg H, Wiklund F, Aly M, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, Mcdonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokołorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Butterbach K, Arndt V, Park JY, Sellers T, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Govindasami K, Guy M, Lophatonanon A, Muir K, Viñuela A, Brown AA; PRACTICAL Consortium; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative; Australian Prostate Cancer BioResource; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators, Freedman M, Conti DV, Easton D, Coetzee GA, Eeles RA, Kote-Jarai Z.

Hum Mol Genet. 2015 Oct 1;24(19):5589-602. doi: 10.1093/hmg/ddv203. Epub 2015 May 29.

4.

Variation between specialist uropatholgists in reporting extraprostatic extension after radical prostatectomy.

Bryant RJ, Schmitt AJ, Roberts IS, Gill PS, Browning L, Brewster SF, Hamdy FC, Verrill C.

J Clin Pathol. 2015 Jun;68(6):465-72. doi: 10.1136/jclinpath-2014-202661. Epub 2015 Mar 19. Erratum in: J Clin Pathol. 2015 Jul;68(7):e2.

PMID:
25792751
5.

Contemporary practice and technique-related outcomes for radical prostatectomy in the UK: a report of national outcomes.

Laird A, Fowler S, Good DW, Stewart GD, Srinivasan V, Cahill D, Brewster SF, McNeill SA; British Association of Urological Surgeons (BAUS).

BJU Int. 2015 May;115(5):753-63. doi: 10.1111/bju.12866. Epub 2014 Oct 22.

6.

NICE guidelines on Prostate Cancer Active Surveillance: is UK practice leading the world?

Streeter EH, Brewster SF; BAUS Section of Oncology.

BJU Int. 2015 Jan;115(1):12-3. doi: 10.1111/bju.12752. Epub 2014 Oct 18. No abstract available.

7.

PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer.

Vickers AJ, Brewster SF.

Br J Med Surg Urol. 2012 Jul 1;5(4):162-168.

8.

Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks.

Turney BW, Kerr M, Chitnis MM, Lodhia K, Wang Y, Riedemann J, Rochester M, Protheroe AS, Brewster SF, Macaulay VM.

Radiother Oncol. 2012 Jun;103(3):402-9. doi: 10.1016/j.radonc.2012.03.009. Epub 2012 Apr 30.

PMID:
22551565
9.

Prostate cancer: to screen or not to screen.

Bailey SJ, Brewster SF.

Arch Esp Urol. 2011 Jun;64(5):406-18. Review. English, Spanish.

PMID:
21705812
10.

Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression.

Turney BW, Turner GD, Brewster SF, Macaulay VM.

BJU Int. 2011 May;107(9):1488-99. doi: 10.1111/j.1464-410X.2010.09556.x. Epub 2010 Sep 14.

11.

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.

Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dörk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF.

Nat Genet. 2009 Oct;41(10):1116-21. doi: 10.1038/ng.450. Epub 2009 Sep 20.

12.

Multiple loci on 8q24 associated with prostate cancer susceptibility.

Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, Leongamornlert DA, Tymrakiewicz M, Jhavar S, Saunders E, Hopper JL, Southey MC, Muir KR, English DR, Dearnaley DP, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Sawyer E, Lophatananon A; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK Prostate testing for cancer and Treatment study (ProtecT Study) Collaborators, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper C, Donovan JL, Hamdy FC, Neal DE, Eeles RA, Easton DF.

Nat Genet. 2009 Oct;41(10):1058-60. doi: 10.1038/ng.452. Epub 2009 Sep 20.

PMID:
19767752
13.

Low-risk localized prostate cancer: are we ready to tell patients that active surveillance is the preferred option?

Brewster SF.

BJU Int. 2008 Sep;102(8):923-6. doi: 10.1111/j.1464-410X.2008.07848.x. Epub 2008 Jul 21. No abstract available.

14.

Mutations in the AXIN1 gene in advanced prostate cancer.

Yardy GW, Bicknell DC, Wilding JL, Bartlett S, Liu Y, Winney B, Turner GD, Brewster SF, Bodmer WF.

Eur Urol. 2009 Sep;56(3):486-94. doi: 10.1016/j.eururo.2008.05.029. Epub 2008 May 23.

PMID:
18514389
15.

THE Wnt signalling pathway is a potential therapeutic target in prostate cancer.

Yardy GW, Brewster SF.

BJU Int. 2006 Oct;98(4):719-21. No abstract available.

16.

Wnt signalling and prostate cancer.

Yardy GW, Brewster SF.

Prostate Cancer Prostatic Dis. 2005;8(2):119-26. Review.

PMID:
15809669
17.

Long-term outcomes and morbidity after I125 brachytherapy for localised prostate cancer: an early UK series.

Hellawell GO, Ho K, Halliwell M, Appleby H, Le Monnier K, Boiangiu I, Davies DR, Fellows G, Whipp E, Brewster SF.

Clin Oncol (R Coll Radiol). 2005 Feb;17(1):68-9. No abstract available.

PMID:
15714935
18.
19.

Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer.

Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM.

Cancer Gene Ther. 2005 Jan;12(1):90-100.

PMID:
15499378
20.

Genetics for urologists.

Rochester MA, Brewster SF.

BJU Int. 2004 Jul;94(2):232-7. Review. No abstract available.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk